Drug Details
| General Information of the Drug (ID: DR1850) | ||||
|---|---|---|---|---|
| Name |
Ultraviolet A irradiation
|
|||
| Molecular Type |
Radiotherapy
|
|||
| Disease | Systemic sclerosis [ICD-11: 4A42] | Phase 2 | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arctigenin | Arctium lappa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Human mesenchymal stem cells derived from adipose tissue | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Arctigenin protects against ultraviolet-A-induced damage to stemness through inhibition of the NF-KappaB/MAPK pathway. | |||||
